Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy
NCT ID: NCT00793975
Last Updated: 2013-08-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
37 participants
INTERVENTIONAL
2005-01-31
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IMC-1121B
All patients will receive intravenous infusions of IMC-1121B with the dose depending on which cohort they are enrolled into. A minimum of three patients will be enrolled in each cohort.
A completed patient will be either a patient who completes the 4-week treatment cycle and 2-week observation period (for a total of 6 weeks), or a patient who discontinues therapy for an IMC-1121B-related toxicity. Toxicity data for each cohort will be reviewed prior to dose escalation.
When all patients complete a cohort, dose escalation to the next cohort will occur.
IMC-1121B
Cohort 1
2 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
1121B
Cohort 2
4 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
1121B
Cohort 3
6 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
1121B
Cohort 4
8 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
1121B
Cohort 5
10 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
1121B
Cohort 6
13 mg/kg once a week for 4 weeks, followed by a 2-week observation period.
1121B
Cohort 7
16 mg/kg once a week for 4 weeks, followed by a 2-week observation period.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IMC-1121B
Cohort 1
2 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
1121B
Cohort 2
4 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
1121B
Cohort 3
6 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
1121B
Cohort 4
8 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
1121B
Cohort 5
10 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.
1121B
Cohort 6
13 mg/kg once a week for 4 weeks, followed by a 2-week observation period.
1121B
Cohort 7
16 mg/kg once a week for 4 weeks, followed by a 2-week observation period.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG performance status score of ≤ 2 at study entry
* Able to provide written informed consent
* A life expectancy of \> 3 months
* Adequate hematologic function, as defined by: ANC ≥ 1500/mm\^3, hemoglobin level ≥ 10 gm/dL, platelet count ≥ 100,000/mm\^3
* Adequate hepatic function, as defined by: total bilirubin level ≤ 1.5 x the ULN, AST and ALT levels ≤ 2.5 x the ULN or ≤ 5 x the ULN if known liver metastases
* Adequate renal function, as defined by a serum creatinine level ≤ 1.5 x the ULN
* Use of effective contraception (per the institutional standard), if procreative potential exists
* Adequate recovery from recent surgery, chemotherapy, and radiation therapy. At least 28 days must have elapsed from major surgery, prior chemotherapy, prior treatment with an investigational agent or device, or prior radiation therapy (palliative radiation therapy is allowed).
* Accessible for treatment and follow-up. Patients enrolled in this trial must be treated at the participating center.
Exclusion Criteria
* Patients who have had chemotherapy or therapeutic radiotherapy within 28 days (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or patients with ongoing side effects ≥ grade 2 due to agents administered more than 28 days earlier.
* Prior left chest wall radiotherapy or a cumulative anthracycline dose ≥ 300mg/m2 (if the ejection fraction is within normal institutional limits, the patient can be enrolled).
* Any concurrent malignancy other than non-melanomatous skin cancer or carcinoma in situ of the cervix. Patients with a previous malignancy but without evidence of disease ≥ 3 years will be allowed to enter the trial.
* Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection requiring parenteral antibiotics, symptomatic congestive heart failure, unstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months, uncontrolled hypertension, clinically significant cardiac arrhythmia, uncontrolled diabetes, psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements, patients with symptomatic brain metastases
* A serious or nonhealing active wound, ulcer, or bone fracture
* Known HIV positivity
* A major surgical procedure, an open biopsy, or a significant injury within 28 days prior to treatment
* Current or recent use (within 28 days) of a thrombolytic agent
* Current or recent use (within 28 days) of full-dose warfarin
* Chronic daily treatment with aspirin (\>325 mg/day) or nonsteroidal anti-inflammatory medications known to inhibit platelet function
* History or clinical evidence of a deep venous or arterial thrombosis (including pulmonary embolism) within 6 months prior to study entry
* Proteinuria ≥1+ by routine urinalysis (patients with a protein value of ≤ 500mg confirmed by a 24-hour urine collection are eligible)
* Pregnant (confirmed by serum beta human chorionic gonadotropin \[βHCG\]) or breast feeding
* Prior treatment with bevacizumab or other agents specifically targeting VEGF ligand or receptor within 6 weeks of study entry
* Monoclonal antibodies within 6 weeks of study entry
* Positive anti-IMC-1121B antibody response
* History of allergic reactions to monoclonal antibodies or other therapeutic proteins
* Employees of the investigator or study center with direct involvement in this study or other studies under the direction of the investigator or study center, as well as family members the employees.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_CHAIR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ImClone Investigational Site
Aurora, Colorado, United States
ImClone Investigational Site
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CP12-0401
Identifier Type: OTHER
Identifier Source: secondary_id
I4T-IE-JVBM
Identifier Type: OTHER
Identifier Source: secondary_id
13918
Identifier Type: -
Identifier Source: org_study_id